Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.

MLA

Liu, Heshu, et al. “Targeting DCLK1 Attenuates Tumor Stemness and Evokes Antitumor Immunity in Triple-Negative Breast Cancer by Inhibiting IL-6/STAT3 Signaling.” Breast Cancer Research : BCR, vol. 25, no. 1, Apr. 2023, p. 43. EBSCOhost, https://doi.org/10.1186/s13058-023-01642-3.

APA

Liu, H., Yan, R., Xiao, Z., Huang, X., Yao, J., Liu, J., An, G., & Ge, Y. (2023). Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling. Breast Cancer Research : BCR, 25(1), 43. https://doi.org/10.1186/s13058-023-01642-3

Chicago

Liu, Heshu, Rui Yan, Zeru Xiao, Xuying Huang, Jiannan Yao, Jian Liu, Guangyu An, and Yang Ge. 2023. “Targeting DCLK1 Attenuates Tumor Stemness and Evokes Antitumor Immunity in Triple-Negative Breast Cancer by Inhibiting IL-6/STAT3 Signaling.” Breast Cancer Research : BCR 25 (1): 43. doi:10.1186/s13058-023-01642-3.